Avalo Therapeutics, Inc. (AVTX)
18.97
-0.37
(-1.91%)
USD |
NASDAQ |
Sep 01, 16:00
18.97
0.00 (0.00%)
After-Hours: 16:30
Avalo Therapeutics Cash from Operations (TTM) : -68.29M for June 30, 2026
Cash from Operations (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | -68.29M |
| March 31, 2026 | -59.69M |
| December 31, 2025 | -51.46M |
| September 30, 2025 | -52.26M |
| June 30, 2025 | -47.42M |
| March 31, 2025 | -52.31M |
| December 31, 2024 | -49.06M |
| September 30, 2024 | -36.78M |
| June 30, 2024 | -32.09M |
| March 31, 2024 | -26.83M |
| December 31, 2023 | -30.68M |
| September 30, 2023 | -31.85M |
| June 30, 2023 | -19.29M |
| March 31, 2023 | -20.74M |
| December 31, 2022 | -26.75M |
| September 30, 2022 | -39.91M |
| June 30, 2022 | -61.93M |
| March 31, 2022 | -68.64M |
| December 31, 2021 | -70.89M |
| September 30, 2021 | -68.17M |
| June 30, 2021 | -63.75M |
| March 31, 2021 | -53.12M |
| Date | Value |
|---|---|
| December 31, 2020 | -40.54M |
| September 30, 2020 | |
| June 30, 2020 | |
| March 31, 2020 | |
| December 31, 2019 | |
| September 30, 2019 | -19.43M |
| June 30, 2019 | -12.35M |
| March 31, 2019 | -5.969M |
| December 31, 2018 | -3.128M |
| September 30, 2018 | -3.702M |
| June 30, 2018 | 15.96M |
| March 31, 2018 | 14.53M |
| December 31, 2017 | 12.58M |
| September 30, 2017 | 11.35M |
| June 30, 2017 | -11.13M |
| March 31, 2017 | -13.09M |
| December 31, 2016 | -14.56M |
| September 30, 2016 | -14.39M |
| June 30, 2016 | -12.91M |
| March 31, 2016 | -10.86M |
| December 31, 2015 | -10.28M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (TTM) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 160.32M |
| Incyte Corp. | 1.980B |
| AbbVie, Inc. | 19.51B |
| Rezolute, Inc. | -73.48M |
| Alnylam Pharmaceuticals, Inc. | 885.89M |